BiotechTube

[¹⁴C]Etelcalcetide

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis

Conditions

Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis

Trial Timeline

Feb 7, 2014 → Aug 15, 2014

NCT ID
NCT02054572

About [¹⁴C]Etelcalcetide

[¹⁴C]Etelcalcetide is a phase 1 stage product being developed by Amgen for Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT02054572. Target conditions include Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis.

What happened to similar drugs?

6 of 20 similar drugs in Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis were approved

Approved (6) Terminated (0) Active (14)
🔄KHK7580Kyowa KirinPhase 3
🔄KHK7580Kyowa KirinPhase 3
✅Cinacalcet HClKyowa KirinApproved
🔄KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
🔄paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02054572Phase 1Completed

Competing Products

20 competing products in Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotide + PlaceboEli LillyPhase 2/3
38
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43